Digital Access & LIVE Q&A
August 22, 2020
Hepatology School: 8.25 CME Credits, 8.25 MOC Points
In order to maximize effective online clinical education, ACG will be offering the Hepatology School as a flexible combination of on-demand education supported by engaging LIVE Q&A with expert faculty. With ACG’s NEW VIRTUAL Hepatology School you’ll receive on-demand access to over 5 hours of recorded lectures delivered by world-class faculty. Each of the 16 lectures will help you improve clinical judgment and address the art and science of liver disease management.
Advance Online Viewing Available: Videos will be available starting on Friday, August 14th. Watch the videos on your own time and have access to them for up to 1 year following the course.
Exclusive Live Q&A If You Register Now! Those who register by Saturday, August 22nd will also receive exclusive access to three LIVE Q&A webcast sessions plus a bonus satellite symposium!
Live Q&A Sessions: Liver disease experts Dr. David Bernstein, Dr. Paul Kwo, and Dr. Mitchell Shiffman will host LIVE Q&A with the Hepatology School faculty on August 22 from 2:00 pm to 2:45 pm and 4:45 pm to 5:30 pm, in addition to a 90-minute case-focused session with the entire faculty from 3:00 pm to 4:30 pm (Eastern Daylight time).Agenda and LIVE Q&A Schedule
Hepatology School Course Directors:
Registration Fees: Hepatology School
|Registration Fee||Registration Category|
|$125||ACG Physician Member / Fellow|
|$125||ACG Candidate/Trainee/Resident Member|
|$125||ACG Advanced Practice Provider / Associate Member|
|$175||Non-Member Physicians / PharmD / PhD / Guest|
|$175||Non-Member Trainee / GI Fellow / Resident|
|$175||Non-Member NP / PA / Allied Health (RN, LPN)|
Saturday, August 22 – 5:45 pm (EDT)
Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know?
Stephen A. Harrison, MD; Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF
Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is a severe liver disorder with a rapidly progressive course that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In order to prevent irreversible liver damage, patients with NASH should receive immediate treatment. However, distinguishing NASH from other liver disorders and identifying high-risk patients remain challenging, and there are limited treatment options once a patient is diagnosed. While there are no approved medical therapies for NASH, multiple investigational agents have shown promise in late-stage trials and are expected to be available for NASH treatment soon.
This activity, Breakthroughs with NASH Management: What Do Gastroenterologists and Hepatologists Need to Know? will provide clinicians with the most current guidance on NASH diagnostic strategies. Clinician learners will also receive information on the efficacy, safety, and potential use of novel agents in late-stage clinical investigation for the treatment of patients with NASH.
*These events are neither sponsored by nor endorsed by ACG.
For more information on supporting this conference through a virtual exhibitor presence, please email firstname.lastname@example.org.
Accreditation / CME / MOC:
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ACG’s Virtual Hepatology School: The American College of Gastroenterology designates this other activity (blended learning) for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 MOC points in the ABIM’s MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The American College of Gastroenterology acknowledges educational grant support for the Hepatology School from Intercept Pharmaceuticals, Inc.